The Discovery

In 1996, Burzin Bhavnagri discovered a single equation with a remarkable property: it produces accurate results regardless of the specific model it is applied to. Rather than deriving a separate mathematical model for each phenomenon — one for fluid dynamics, another for electrical circuits, another for biochemical pathways — the All Model equation operates independently of the underlying model. It does not need to know what the model is. It works anyway.

This discovery has since driven research across multiple scientific and commercial domains, each one a different expression of the same underlying principle.

What Makes It Universal

Most mathematical models are built from the ground up for a specific phenomenon. They encode assumptions about the system — assumptions that fail when those conditions change. The All Model equation makes no such assumptions. Even when several phenomena interact simultaneously — chemical reactions, electrical signals, oxygen flow, cellular behaviour, genomic expression — the equation remains valid. The unknown model is treated as a constant, and the equation resolves around it.

This has two consequences that matter in practice. First, it dramatically reduces the time required to model a new system: there is no need to derive the governing equations from first principles each time. Second, it enables precision that would otherwise be computationally or experimentally prohibitive — including, in life sciences applications, the ability to target exactly one molecule out of many millions.

Applications

The All Model equation has been applied to problems across several fields:

  • Physics — modelling interacting physical systems without pre-specifying the governing relations between variables
  • Chemistry — identifying molecular targets within complex reaction environments
  • Electronics — circuit and signal analysis across varying operating conditions
  • Finance — modelling market behaviour where the underlying generative process is unknown or unstable
  • Life sciences — the most commercially significant application to date, enabling the development of novel therapeutic compounds for inherited retinal diseases

Precision Targeting in Life Sciences

In biological research, the challenge is often not identifying that a molecule is involved in a process — it is isolating that molecule from the millions of structurally similar compounds present in a living system. The All Model equation makes this tractable. By treating the biological system as an unknown model and applying the equation, All Model Pty Ltd has been able to identify and synthesise specific retinal analog compounds that interact with the visual cycle in a predictable and measurable way.

This approach also has significant implications for animal welfare in research. The precision of the targeting means that fewer experimental compounds need to be screened, and concentrations can be established with greater confidence before animal testing commences.

Pharmaceutical Platform

The life sciences application of the All Model equation has produced the company's pharmaceutical pipeline — novel opsin protein therapeutics targeting vision cycle disorders including Leber Congenital Amaurosis (LCA), Stargardt disease and Retinitis Pigmentosa. These compounds are being developed under the name RecoverSight and are currently available for research use.

The same mathematical foundation that underpins this work continues to be applied across All Model's broader research programme. New model domains are continuously being evaluated.